Pain and mild cognitive impairment among adults aged 50 years and above residing in low- and middle-income countries.


Journal

Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 14 02 2023
accepted: 04 05 2023
medline: 23 6 2023
pubmed: 25 5 2023
entrez: 25 5 2023
Statut: ppublish

Résumé

Previous studies on the association between pain and cognitive decline or impairment have yielded mixed results, while studies from low- and middle-income countries (LMICs) or specifically on mild cognitive impairment (MCI) are scarce. Thus, we investigated the association between pain and MCI in LMICs and quantified the extent to which perceived stress, sleep/energy problems, and mobility limitations explain the pain/MCI relationship. Data analysis of cross-sectional data from six LMICs from the Study on Global Ageing and Adult Health (SAGE) were performed. MCI was based on the National Institute on Aging-Alzheimer's Association criteria. "Overall in the last 30 days, how much of bodily aches or pain did you have?" was the question utilized to assess pain. Associations were examined by multivariable logistic regression analysis and meta-analysis. Data on 32,715 individuals aged 50 years and over were analysed [mean (SD) age 62.1 (15.6) years; 51.7% females]. In the overall sample, compared to no pain, mild, moderate, and severe/extreme pain were dose-dependently associated with 1.36 (95% CI = 1.18-1.55), 2.15 (95% CI = 1.77-2.62), and 3.01 (95% CI = 2.36-3.85) times higher odds for MCI, respectively. Mediation analysis showed that perceived stress, sleep/energy problems, and mobility limitations explained 10.4%, 30.6%, and 51.5% of the association between severe/extreme pain and MCI. Among middle-aged to older adults from six LMICs, pain was associated with MCI dose-dependently, and sleep problems and mobility limitations were identified as potential mediators. These findings raise the possibility of pain as a modifiable risk factor for developing MCI.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies on the association between pain and cognitive decline or impairment have yielded mixed results, while studies from low- and middle-income countries (LMICs) or specifically on mild cognitive impairment (MCI) are scarce. Thus, we investigated the association between pain and MCI in LMICs and quantified the extent to which perceived stress, sleep/energy problems, and mobility limitations explain the pain/MCI relationship.
METHODS METHODS
Data analysis of cross-sectional data from six LMICs from the Study on Global Ageing and Adult Health (SAGE) were performed. MCI was based on the National Institute on Aging-Alzheimer's Association criteria. "Overall in the last 30 days, how much of bodily aches or pain did you have?" was the question utilized to assess pain. Associations were examined by multivariable logistic regression analysis and meta-analysis.
RESULTS RESULTS
Data on 32,715 individuals aged 50 years and over were analysed [mean (SD) age 62.1 (15.6) years; 51.7% females]. In the overall sample, compared to no pain, mild, moderate, and severe/extreme pain were dose-dependently associated with 1.36 (95% CI = 1.18-1.55), 2.15 (95% CI = 1.77-2.62), and 3.01 (95% CI = 2.36-3.85) times higher odds for MCI, respectively. Mediation analysis showed that perceived stress, sleep/energy problems, and mobility limitations explained 10.4%, 30.6%, and 51.5% of the association between severe/extreme pain and MCI.
CONCLUSIONS CONCLUSIONS
Among middle-aged to older adults from six LMICs, pain was associated with MCI dose-dependently, and sleep problems and mobility limitations were identified as potential mediators. These findings raise the possibility of pain as a modifiable risk factor for developing MCI.

Identifiants

pubmed: 37227581
doi: 10.1007/s40520-023-02434-7
pii: 10.1007/s40520-023-02434-7
pmc: PMC10284948
doi:

Types de publication

Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1513-1520

Subventions

Organisme : NIA NIH HHS
ID : R01 AG034479
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG034263
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Am Geriatr Soc. 2018 Apr;66(4):721-727
pubmed: 29427504
Alzheimers Dement. 2014 Jun;10(3 Suppl):S155-65
pubmed: 24924667
J Psychiatr Res. 2016 Jun;77:109-15
pubmed: 27017287
Int J Methods Psychiatr Res. 2004;13(2):93-121
pubmed: 15297906
Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):93-8
pubmed: 26655068
J Affect Disord. 2018 Mar 15;229:231-238
pubmed: 29329054
Exp Gerontol. 2021 Oct 15;154:111513
pubmed: 34384889
Biomed Res Int. 2017;2017:9016924
pubmed: 28271072
Front Neurosci. 2021 Sep 22;15:737874
pubmed: 34630023
Clin J Pain. 2011 Feb;27(2):169-81
pubmed: 20842008
PLoS One. 2014 Dec 05;9(12):e114742
pubmed: 25478876
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):404-18
pubmed: 27042901
J Pain Res. 2016 Jun 28;9:457-67
pubmed: 27418853
Pain Pract. 2014 Jan;14(1):E1-7
pubmed: 23701810
Arch Neurol. 2010 Aug;67(8):980-6
pubmed: 20697049
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
Arch Intern Med. 2001 Jul 23;161(14):1703-8
pubmed: 11485502
Dementia (London). 2019 Jan;18(1):380-390
pubmed: 27758960
J Alzheimers Dis. 2020;78(3):1177-1195
pubmed: 33252087
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Dec 20;87(Pt B):183-192
pubmed: 28797640
Gerontology. 2019;65(2):155-163
pubmed: 30199870
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Maturitas. 2018 Sep;115:92-96
pubmed: 30049353
J Pain Palliat Care Pharmacother. 2011;25(1):6-18
pubmed: 21426212
J Sleep Res. 2021 Dec;30(6):e13395
pubmed: 34080234
Chronic Stress (Thousand Oaks). 2017 Feb;1:
pubmed: 28795169
Int J Epidemiol. 2012 Dec;41(6):1639-49
pubmed: 23283715
Ann Neurol. 2018 Jan;83(1):197-204
pubmed: 29220873
Can J Psychiatry. 2002 Nov;47(9):844-8
pubmed: 12500754

Auteurs

Lee Smith (L)

Centre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.

Guillermo F López Sánchez (GF)

Division of Preventive Medicine and Public Health, Department of Public Health Sciences, School of Medicine, University of Murcia, Murcia, Spain. gfls@um.es.

Jae Il Shin (JI)

Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.

Pinar Soysal (P)

Department of Geriatric Medicine, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.

Damiano Pizzol (D)

Italian Agency for Development Cooperation, Khartoum, Sudan.

Yvonne Barnett (Y)

Centre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.

Karel Kostev (K)

University Clinic of Marburg, Marburg, Germany.

Louis Jacob (L)

Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Dr. Antoni Pujadas, Sant Boi de Llobregat, Barcelona, Spain.
Department of Physical and Rehabilitation Medicine, Lariboisière-Fernand Widal Hospital, AP-HP, University Paris Cité, Paris, France.

Nicola Veronese (N)

Department of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy.

Laurie Butler (L)

Centre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.

Helen Odell-Miller (H)

Cambridge Institute for Music Therapy Research, Anglia Ruskin University, Cambridge, UK.

Jodie Bloska (J)

Cambridge Institute for Music Therapy Research, Anglia Ruskin University, Cambridge, UK.

Benjamin R Underwood (BR)

Department of Psychiatry, University of Cambridge, Herchel Smith Building, Forvie Site, Robinson Way, Cambridge , CB2 0SZ, UK.
Cambridgeshire and Peterborough NHS Foundation Trust, Windsor Unit, Fulbourn Hospital, Cambridge, CB21 5EF, UK.

Ai Koyanagi (A)

Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Dr. Antoni Pujadas, Sant Boi de Llobregat, Barcelona, Spain.
ICREA, Pg. Lluis Companys 23, 08010, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH